| Entry |
|
|---|
| Name |
Certolizumab pegol (genetical recombination) (JAN);
Certolizumab pegol (USAN/INN);
Cimzia (TN)
|
|---|
| Product |
|
|---|
| Formula |
C2115H3252N556O673S16
|
|---|
| Exact mass |
47719.2868
|
|---|
| Mol weight |
47748.8128
|
|---|
| Activity |
Treatment of rheumatoid arthritis and inflammatory bowel disease, specifically Crohn's disease [DS: H00286]
|
|---|
| Remark |
Therapeutic category: ATC code: |
|---|
| Comment |
Indication: Crohn's disease
humanized Fab, pegylated
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
| Antirheumatics - DMARDs and biological agents |
|
|---|
| Brite |
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D03441 Certolizumab pegol (genetical recombination) (JAN); Certolizumab pegol (USAN/INN)
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
L04AB05 Certolizumab pegol
D03441 Certolizumab pegol (genetical recombination) (JAN); Certolizumab pegol (USAN/INN)
USP drug classification [BR:br08302]
Immunological Agents
Immune Suppressants
Tumor Necrosis Factor (TNF) Blockers
Certolizumab pegol
D03441 Certolizumab pegol (genetical recombination) (JAN); Certolizumab pegol (USAN/INN)
Target-based classification of drugs [BR:br08310]
Cytokines
TNF family
TNF-alpha [HSA:7124] [KO:K03156]
Certolizumab pegol [ATC:L04AB05]
D03441 Certolizumab pegol (genetical recombination) (JAN); Certolizumab pegol (USAN/INN)
 |
|---|
| Other DBs |
|
|---|
